Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT-HF
2017-000697-11Phase 3Suspended
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) comparing Spironolactone with Placebo (2 arms). Started Dec 2017; status: suspended.
02
Drugs
spironolactone
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2017-000697-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000697-11.